Vor Biopharma (VOR)
(Delayed Data from NSDQ)
$1.01 USD
-0.04 (-3.81%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $1.03 +0.02 (1.98%) 6:20 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
VOR 1.01 -0.04(-3.81%)
Will VOR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VOR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VOR
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
VOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295%
Other News for VOR
Vor Bio announces new clinical data from VBP101 study
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
New Clinical Data Validates Vor Bio?s Approach of Using Shielded Transplants to Deliver Targeted Therapies
Vor Bio announces new data, plans to approach FDA on trial design by year-end
Vor Bio stock rallies post-market on trem-cel study data